{"id":"NCT00825812","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Comparison of 2.0 mg/kg Sugammadex and Neostigmine at Reappearance of T2 in Chinese and European Subjects (Study 19.4.324)(P05768AM1)(COMPLETED)","officialTitle":"A Multi-center, Randomized, Parallel-group, Active-controlled, Safety-assessor Blinded Trial, Comparing the Efficacy and Safety of 2.0 mg.Kg-1 Sugammadex With 50 μg.Kg-1 Neostigmine Administered at Reappearance of T2 After Rocuronium in Chinese and European ASA I-III Subjects Undergoing Elective Surgery Under Propofol Anesthesia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-01","primaryCompletion":"2010-09","completion":"2010-09","firstPosted":"2009-01-21","resultsPosted":"2011-08-18","lastUpdate":"2015-11-02"},"enrollment":308,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"TREATMENT"},"conditions":["Anesthesia, General","Neuromuscular Blockade"],"interventions":[{"type":"DRUG","name":"Sugammadex","otherNames":["Org 25969, Bridion®"]},{"type":"DRUG","name":"neostigmine","otherNames":["Neostigmine with atropine"]}],"arms":[{"label":"Sugammadex in Caucasian Subjects","type":"EXPERIMENTAL"},{"label":"Neostigmine in Caucasian Subjects","type":"ACTIVE_COMPARATOR"},{"label":"Sugammadex in Chinese Subjects","type":"EXPERIMENTAL"},{"label":"Neostigmine in Chinese Subjects","type":"ACTIVE_COMPARATOR"}],"summary":"The present trial was set up to evaluate the efficacy and safety of 2.0 mg.kg-1 sugammadex compared to neostigmine administered at reappearance of T2 in Chinese and Caucasian subjects for registration purposes in China.","primaryOutcome":{"measure":"Time From Start of Administration of Investigational Medicinal Product (IMP) to Recovery of the T4/T1 Ratio to 0.9.","timeFrame":"start of administration of sugammadex/neostigmine to recovery from neuromuscular blockade","effectByArm":[{"arm":"Sugammadex in Caucasian Subjects","deltaMin":1.4,"sd":null},{"arm":"Neostigmine in Caucasian Subjects","deltaMin":6.7,"sd":null},{"arm":"Sugammadex in Chinese Subjects","deltaMin":1.6,"sd":null},{"arm":"Neostigmine in Chinese Subjects","deltaMin":9.1,"sd":null}],"pValues":[{"comp":"OG002 vs OG003","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG002","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["25187755"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":29},"commonTop":["Incision site pain","Procedural pain","Pyrexia","Dizziness","Nausea"]}}